		Case 2:24-cv-02427-TLN-SCR	Document 29	Filed 08/11/25	Page 1 of 24	
3 4 5 6 6 7 7 8 8 9 10 UNITED STATES DISTRICT COURT 11 EASTERN DISTRICT OF CALIFORNIA 12 13 14 ALANA GUTIERREZ, No. 2:24-cv-02427-TLN-SCR 15 Plaintiff, V. ORDER 17 ABBOTT LABORATORIES, Defendant. 19 10 Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part. 19 11 11 11 11 11 11 11 11 11 11 11 11	1					
UNITED STATES DISTRICT COURT  EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, No. 2:24-cv-02427-TLN-SCR  Plaintiff, v. ORDER  ABBOTT LABORATORIES, Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  Here is a control of the court of the court of the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  Here is a control of the court of the court of the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.	2					
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, Plaintiff, V. ORDER  ABBOTT LABORATORIES, Befendant.  This matter is before the Court on Defendant Abbott Laboratorics' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  //// /// /// /// /// /// /// /// ///	3					
0 UNITED STATES DISTRICT COURT 11 EASTERN DISTRICT OF CALIFORNIA 12 13 14 ALANA GUTIERREZ, Plaintiff, v. ORDER 17 ABBOTT LABORATORIES, 18 Defendant. 19 20 This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motic 21 to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 21.) For the reasons set forth below, Defendant's motic 23 is GRANTED in part and DENIED in part. 24 25 26 27 27 28	4					
UNITED STATES DISTRICT COURT  EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, No. 2:24-cv-02427-TLN-SCR  Plaintiff,  V. ORDER  ABBOTT LABORATORIES,  Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motic to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motic is GRANTED in part and DENIED in part.  ///  ///  ///  ///  ///  ///  ///	5					
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, No. 2:24-cv-02427-TLN-SCR Plaintiff, V. ORDER  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  /// /// /// /// /// /// /// /// ///	6					
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, Plaintiff, v. ORDER  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.    With the countries of the court of the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.    With the countries of the court of the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.	7					
UNITED STATES DISTRICT COURT  EASTERN DISTRICT OF CALIFORNIA  ALANA GUTIERREZ, No. 2:24-cv-02427-TLN-SCR  Plaintiff,  v. ORDER  ABBOTT LABORATORIES,  Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motic to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motic is GRANTED in part and DENIED in part.  ///  ///  ///  ///  ///  ///  ///	8					
EASTERN DISTRICT OF CALIFORNIA  12 13 14     ALANA GUTIERREZ,	9					
12 13 14 ALANA GUTIERREZ, Plaintiff, 16 v. ORDER  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motic to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motic is GRANTED in part and DENIED in part.  24 25 26 27 28	10	UNITED STATES DISTRICT COURT				
ALANA GUTIERREZ, Plaintiff, V. ABBOTT LABORATORIES, Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motic to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motic is GRANTED in part and DENIED in part.  /// /// /// /// /// /// /// /// ///	11	EASTERN DISTRICT OF CALIFORNIA				
ALANA GUTIERREZ, Plaintiff,  V. ORDER  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  /// /// /// /// /// /// /// /// ///	12					
Plaintiff,  V. ORDER  ABBOTT LABORATORIES,  Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  ///  ///  ///  ///  ///  ///  ///	13					
ORDER  ABBOTT LABORATORIES, Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.    Matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion is GRANTED in part and DENIED in part.    Matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion is GRANTED in part and DENIED in part.    Matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion is GRANTED in part and DENIED in part.    Matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion is GRANTED in part and DENIED in part.	14	ALANA GUTIERREZ,	N	To. 2:24-cv-02427-T	LN-SCR	
ABBOTT LABORATORIES,  Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  /// /// /// /// /// /// /// /// ///	15	Plaintiff,				
Defendant.  This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  ///  ///  ///  ///  ///  ///  ///	16	v.	O	PRDER		
This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.    19.		ABBOTT LABORATORIES,				
This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.    19.		Defendant.				
to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  ///  ///  ///  ///  ///  ///  ///						
19.) Defendant filed a reply. (ECF No. 21.) For the reasons set forth below, Defendant's motion is GRANTED in part and DENIED in part.  24 /// 25 /// 27 /// 28		This matter is before the Court on Defendant Abbott Laboratories' ("Defendant") Motion				
is GRANTED in part and DENIED in part.    13		to Dismiss. (ECF No. 18.) Plaintiff Alana Gutierrez ("Plaintiff") filed an opposition. (ECF No.				
24		,	,	ne reasons set forth l	below, Defendant's motion	
25			ED in part.			
<ul> <li>26 ///</li> <li>27 ///</li> <li>28</li> </ul>						
27 /// 28						
28						
		///				
	۷۵		1			

### I. FACTUAL AND PROCEDURAL BACKGROUND<sup>1</sup>

The instant putative class action arises from Defendant's allegedly deceptive and unlawful practices in labeling and marketing Go & Grow 360 Total Care by Similac Toddler Drink ("Go & Grow" or the "Product"). (ECF No. 1.) Defendant manufactures, distributes, markets, advertises, and sells toddler drink products under the brand name Go & Grow. (*Id.* at 3.) These products have packaging that predominantly, uniformly, and consistently make nutrient content claims on the principal display panel of the product labels. (*Id.*) The Product is intended for children under the age of two and is labeled with the intended age on the front label, "12-36 MONTHS." (*Id.* at 3–4.)

Plaintiff alleges Defendant misbrands the Product by making nutrient content claims on packages that are strictly prohibited by the U.S. Food and Drug Administration ("FDA"). (*Id.* at 2.) Plaintiff further alleges the nutrient content claims on the Product mislead purchasers into believing it provides physical health benefits for children under two years of age in order to induce parents into purchasing it, but the Product is harmful both nutritionally and developmentally for children under two. (*Id.*)

According to Plaintiff, the Product is unlawful, misbranded, and violates the Sherman Law, California Health & Safety Code § 110660, et seq., because the Product is intended for children less than two years of age and the Product's label contains nutrient content claims. (*Id.* at 7.) Plaintiff alleges the Product at issue in this case is intended for children one year and up as evidenced on the front label and in the Product title. (*Id.* at 7–8.) Plaintiff alleges the Product is also sold in the "baby food" grocery store aisles, alongside infant formulas. (*Id.* at 8.) Plaintiff alleges, on information and belief, Defendant directs retailers to sell the Product in the baby food aisle. (*Id.*) Plaintiff further alleges Defendant misbrands the Product by making nutrient content claims that are strictly prohibited by the FDA, and by misleading purchasers into believing that its Product provides physical health benefits in order to induce parents into purchasing the Product. (*Id.*)

The following factual background is taken largely verbatim from Plaintiff's Complaint. (ECF No. 1.)

## ase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 4 of 24

The Product's front and back labels contain nutrient content claims that are allegedly unlawful. (*Id.*) The Product prominently states nutrient content claims on the front label such as "✓ IMMUNE SUPPORT;" "✓ BRAIN DEVELOPMENT;" "✓ DIGESTIVE HEALTH;" "DHA, LUTEIN, VITAMIN E;" and "5 HMO PREBIOTICS." (*Id.*) Further, the Product's back label states: "2 servings have: 28 IMPORTANT NUTRIENTS for GROWTH and DEVELOPMENT;" and "At least 40% of the Daily Value: Iron • Calcium • Vitamins C, D & E." (*Id.*) The terms "IMMUNE SUPPORT, BRAIN DEVELOPMENT, and DIGESTIVE HEALTH" in conjunction with prominent images of checkmarks; "5 HMO PREBIOTICS;" "28 IMPORTANT NUTRIENTS for GROWTH and DEVELOPMENT" are each implied nutrient content claims. (*Id.*) Plaintiff alleges the statement "At least 40% of the Daily Value: Iron • Calcium • Vitamins C, D & E" is an express nutrient content claim, or, in the alternative, it is an implied nutrient claim. (*Id.*)

Exhibit 2 to Plaintiff's Complaint contains pictures of the labels for the Product:





INSTRUC

sippy cup.

Añada 4 oz fl de agua a ra taza limpia.

Store unopened and

temperatures, Once

Almacene el recipier

USE BY DATE OF CAR

1 NOT FOR CHILDREN WITH GALACTOSEMIA 2 NO APTO PARA NIÑOS CON GALACTOSEMIA INCREDIENTS: NONFAT MILK, LACTOSE, HIGH OLDIC SAFFLOWER OIL, SOYOL, COCONUT OIL, HUMAN MIK OUGOSACCHARIDES (2'-FUCOSYLLACTOSE, LACTO-N-TETRAOSE, 3-FUCOSYLLACTOSE 3 6-SIALVILACTOSE, 3'-SIALVILACTOSE); LESS THAN 2% OF: CALCIUM PHOSPHATE, POTASSIAM PRODUCE CHOLINE CHLORIDE, ASCORBIC ACID, SOY LECTHIN, INOSTOL, POTASSUM PHOSPHATE SCHZOCHYTRIUM SP. OIL, FERROUS SULFATE, TAURINE, ASCORBYL PALMITATE 4 GALPHA-TOCOPHERY, ACETATE, MORED TOCOPHEROLS, ZINC SULFATE, MACHAMDE POTASSI M DIRATE, CALDUM PANTOTHENATE, RIBOFLAVIN, MANGANESE SULFATE, THAMINE HICROCHLORDE PIRDOUNE HOROCHLORIDE, COPPER SULFATE, VITAMIN A PALMITATE, POTASSILMI CODE, LUTEN. 5 FOLIC ACID, BETA-CAROTENE, CHROMIUM CHLORIDE, SODIUM MOLYBDATE, VITAMIN D., PHYLLOGUsocons (15 g) powder NONE, SODIUM SELENATE, CALCIUM CAPBONATE, MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE undas (15 g) de polvo 6 SALT, BIOTIN, AND VITAMIN B., CONTAINS MILK AND SOY INGREDIENTS. INGREDIENTES: LECHE DESCREMADA, LACTOSA, ACETTE DE CÁRTAMO DE ALTO CONTENDO OLECO, ACEITE DE SOJA, ACEITE DE COCO, OLIGOSACÁRIDOS DE LA LECHE MATERINA<sup>†</sup> (2º FUCOSILACTOSA 7 LACTO H-TETRAOSA, 3-FLOOSLACTOSA, 6'-SIALLACTOSA, 3'-SIALLACTOSA; MENOS DEL 2% DE.
FOSFATO DE CALDO, HORÓXDO DE POTASIO, CLORUPO DE COLINA, ÁCIDO ASCÓPBICO, LECTINA DE SOJA, MOSITOL, FOSFATO DE POTASIO, ACEITE DE SCHIZOCHYTRIUM SP., SULFATO FERROSO 8 TAURINA, PALMITATO DE ASCORBILO, ACETATO DE d-ALFA-TOCOFEROL, TOCOFEROLES MIXTOS SLIFATO DE ZINC, NACINAMIDA, CITRATO DE POTASIO, PANTOTENATO DE CALCIO, RECFLAMA SLIFATO DE MANGANESO, CLORHORATO DE TIAMINA, CLORHORATO DE PRIDOXINA, SLIFATO mail: abinitrates totales 7 g tre detaria O g CÚPRICO, PALMITATO DE VITAMINA A, YOOURO DE POTASIO, LUITEÍNA, ÁCIDO FÓLICO, BETACARDTENO, 9 CLORUPO DE CROMO, MOLIBOATO DE SODIO, VITAMINA D., FILOQUINONA, SELENATO DE SODIO, CARcares totales 7 g BONATO DE CALCID, CLORURO DE MAGNESIO, CLORURO DE POTASIO, SAL, BIOTINA Y VITAMINA 8., त्यम्बर्गात्रकार्यके विश्व CONTIENE INGREDIENTES DE LECHE Y DE SOJA 10 Abbott Nutrition, Abbott Laboratories 15% Columbus, Ohio 43219-3034 USA HMO, NOT FROM HUMAN MILK. 11 SOURCE OF DHA.

DAILY VALUE FOR 1-TO 3-YEAR OLDS. na C 35% HMO, NO PROVENIENTE DE LA LECHE MATERNA 12 15% FUENTE DE DHA. "VALOR DIARIO PARA NIÑOS DE 1 A 3 AÑOS. Bo 25% GLUTEN FREE 25% 13 SIN GLUTEN 20% nesio 8% 2 servings have: 14 28 Important Nutrients for Growth and Development At least 40% of the Daily Val on • Calcium • Vitamins C 15 2 porciones tienen: 28 nutrientes importantes para el crecimiento y el desarrollo 16 Al menos el 40% del valor diario de Hierro • Calcio • Vitaminas C, D y 17 (ECF No. 1-2 at 3-4.) 18 19 20 21 22 23 24

25

26

27

28

Plaintiff alleges foods intended for children less than two are prohibited from making such nutrient content claims and such claims are also separately misleading. (ECF No. 1 at 8–9 (citing 21 C.F.R. § 101.13(b)(3)).) Plaintiff further alleges reasonable consumers rely on the label claims to decide to purchase the Product for children under two years old. (*Id.* at 9.) These consumers shopping in the baby food aisle of a grocery store or online see the Product alongside products intended for children as young as six months and purchase the Product for their toddler under the age of two. (*Id.*)

In or around July 2021, Plaintiff purchased the Product for her child when he was one year old. (*Id.* at 15.) Plaintiff purchased the Product consistently for about five to six months thereafter, approximately two to three cases of the Product per month (one case includes six

### case 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 6 of 24

individual Products). (*Id.*) Plaintiff purchased the Product from Target, Walmart, and/or WinCo Foods locations in Shingle Springs, California. (*Id.*) Plaintiff viewed both the advertising for the Product and the Product's packaging prior to purchasing it for the first time, and she alleges she purchased it in reliance on the representations on the packaging that the Product provides physical health benefits for children under two years of age. (*Id.*) Plaintiff alleges that because of Defendant's unlawful and misleading nutrient content claims, the Product has no or, at a minimum, much lower value to Plaintiff. (*Id.*) Plaintiff alleges she not only purchased the Product because the label contained nutrient content claims, but she also paid more money for the Product than she would have paid if it did not contain those claims. (*Id.*)

Plaintiff filed the instant putative class action in this Court on September 5, 2024. (ECF No. 1.) Plaintiff's Complaint alleges the following claims: (1) violation of the California Consumer Legal Remedies Act ("CLRA"), Cal. Civ. Code § 1750, et seq.; (2) violation of the California Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code § 17200, et seq.; (3) false advertising in violation of Cal. Bus. & Prof. Code § 17500, et seq.; (4) common law fraud, deceit, and/or misrepresentation; (5) unjust enrichment; and (6) violation of the California False Advertising Law ("FAL"), Cal. Bus. & Prof. Code § 17501.<sup>2</sup> (*Id.*) Defendant filed the instant motion to dismiss on November 8, 2024. (ECF No. 18.)

### II. STANDARD OF LAW

A motion to dismiss for failure to state a claim upon which relief can be granted under Federal Rule of Civil Procedure ("Rule") 12(b)(6) tests the legal sufficiency of a complaint. *Navarro v. Block*, 250 F.3d 729, 732 (9th Cir. 2001). Rule 8(a) requires that a pleading contain "a short and plain statement of the claim showing that the pleader is entitled to relief." *See Ashcroft v. Iqbal*, 556 U.S. 662, 678–79 (2009). Under notice pleading in federal court, the complaint must "give the defendant fair notice of what the claim . . . is and the grounds upon which it rests." *Bell Atlantic v. Twombly*, 550 U.S. 544, 555 (2007) (internal quotations omitted).

Plaintiff styles the sixth claim on the first page of her Complaint as "(6) injunctive relief." (ECF No. 1 at 1.) However, the body of the Complaint refers to this claim as a violation of the FAL. (*Id.* at 28–29.) Accordingly, the Court refers to it as the FAL claim here.

## ase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 7 of 24

"This simplified notice pleading standard relies on liberal discovery rules and summary judgment motions to define disputed facts and issues and to dispose of unmeritorious claims." *Swierkiewicz v. Sorema N.A.*, 534 U.S. 506, 512 (2002).

On a motion to dismiss, the factual allegations of the complaint must be accepted as true. *Cruz v. Beto*, 405 U.S. 319, 322 (1972). A court is bound to give the plaintiff the benefit of every reasonable inference to be drawn from the "well-pleaded" allegations of the complaint. *Retail Clerks Int'l Ass'n v. Schermerhorn*, 373 U.S. 746, 753 n.6 (1963). A plaintiff need not allege "specific facts' beyond those necessary to state his claim and the grounds showing entitlement to relief." *Twombly*, 550 U.S. at 570.

Nevertheless, a court "need not assume the truth of legal conclusions cast in the form of factual allegations." *U.S. ex rel. Chunie v. Ringrose*, 788 F.2d 638, 643 n.2 (9th Cir. 1986). While Rule 8(a) does not require detailed factual allegations, "it demands more than an unadorned, the defendant-unlawfully-harmed-me accusation." *Iqbal*, 556 U.S. at 678. A pleading is insufficient if it offers mere "labels and conclusions" or "a formulaic recitation of the elements of a cause of action." *Twombly*, 550 U.S. at 555; *see also Iqbal*, 556 U.S. at 678 ("Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice."). Moreover, it is inappropriate to assume the plaintiff "can prove facts that it has not alleged or that the defendants have violated the . . . laws in ways that have not been alleged." *Associated Gen. Contractors of Cal., Inc. v. Cal. State Council of Carpenters*, 459 U.S. 519, 526 (1983).

Ultimately, a court may not dismiss a complaint in which the plaintiff has alleged "enough facts to state a claim to relief that is plausible on its face." *Iqbal*, 556 U.S. at 697 (quoting *Twombly*, 550 U.S. at 570). "A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." *Id.* at 680. While the plausibility requirement is not akin to a probability requirement, it demands more than "a sheer possibility that a defendant has acted unlawfully." *Id.* at 678. This plausibility inquiry is "a context-specific task that requires the reviewing court to draw on its judicial experience and common sense." *Id.* at 679.

## ase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 8 of 24

In ruling on a motion to dismiss, a court may only consider the complaint, any exhibits thereto, and matters which may be judicially noticed pursuant to Federal Rule of Evidence 201. See Mir v. Little Co. of Mary Hosp., 844 F.2d 646, 649 (9th Cir. 1988); Isuzu Motors Ltd. v. Consumers Union of U.S., Inc., 12 F. Supp. 2d 1035, 1042 (C.D. Cal. 1998).

If a complaint fails to state a plausible claim, "[a] district court should grant leave to amend even if no request to amend the pleading was made, unless it determines that the pleading could not possibly be cured by the allegation of other facts." *Lopez v. Smith*, 203 F.3d 1122, 1130 (9th Cir. 2000) (en banc) (quoting *Doe v. United States*, 58 F.3d 494, 497 (9th Cir. 1995)).

### III. ANALYSIS

Defendant moves to dismiss Plaintiff's UCL claim under the "unlawful" prong, her fraud claim, her UCL claim under the "unfair" prong, her unjust enrichment claim, and her injunctive relief claim. (ECF No. 18-1 at 10–22.) The Court will address each of these arguments in turn.

### A. UCL "Unlawful" Claim

Plaintiff alleges federal regulations provide that, subject to several exceptions, "no nutrient content claims may be made on food intended specifically for use by infants and children less than [two] years of age." (ECF No. 1 at 4 (citing 21 C.F.R. § 101.13(b)(3)).) Plaintiff alleges the Sherman Food, Drug, and Cosmetic Act ("Sherman Law"), California Health & Safety Code § 110660, incorporates this regulation. (*Id.* at 7, 21.) Plaintiff alleges the statements on the Product's label constitute an impermissible nutrient content claim under federal regulations, which makes it an impermissible nutrient content claim under state law, violating the UCL's "unlawful" prong. (*Id.* at 21.)

Defendant separates the individual statements from the Product's label into five different statements ((1) "✓ IMMUNE SUPPORT," "✓ BRAIN DEVELOPMENT," and "✓ DIGESTIVE HEALTH," (2) "DHA, LUTEIN, VITAMIN E," (3) "5 HMO PREBIOTICS," (4) "2 servings have: 28 Important Nutrients for Growth and Development," (5) "At least 40% of the Daily Value: Iron • Calcium • Vitamins C, D & E), and contend that none of them are implied nutrient content claims. (ECF No. 18-1 at 11–14.) The Court will consider Defendant's arguments about the first, second, and fourth statements together, then consider its arguments about the third

## ase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 9 of 24

statement, and finally consider its arguments about the fifth statement.

*i. First, Second, and Fourth Statements* 

Defendant argues the first, second, and fourth statements are conclusory and therefore Plaintiff's argument that the statement is an implied nutrient content claim fails. (*Id.* (citing *Clemmons v. Upfield US Inc.*, 667 F. Supp. 3d 5, 14 (S.D.N.Y. 2023); *Red v. Kraft Foods, Inc.*, 754 F. Supp. 2d 1137, 1142 (C.D. Cal. 2010)).) In opposition, Plaintiff maintains its UCL unlawful claims are well pleaded, as the Complaint sets forth the specific statements involved, explains why they constitute implied and/or express nutrient content claims, and explains why the labels are false, misleading, and capable of deceiving or confusing the general public. (ECF No. 19 at 16 (citing ECF No. 19 17, 37–39, 42–61).) Plaintiff maintains Defendant designs its label to be read as a whole, courts analyze labels the same way, and the FDA similarly "recognizes statements can be implied nutrient content claims where the term is used in a nutritional context if it appears in association with an explicit or implicit claim or statement about a nutrient." (*Id.* at 17 (citing *LeGrand v. Abbott Labs.*, 655 F. Supp. 3d 871, 899 (N.D. Cal. 2023)).)

California's UCL prohibits unfair competition, including unlawful, unfair, and fraudulent business acts. *Korea Supply Co. v. Lockheed Martin Corp.*, 29 Cal. 4th 1134, 1143 (2003) (citing Cal. Bus. & Prof. Code § 17200(2)(a)). "To state a claim under the unlawful prong of the UCL, a plaintiff must plead: (1) a predicate violation[;] and (2) an accompanying economic injury caused by the violation." *Roper v. Big Heart Pet Brands, Inc.*, 510 F. Supp. 3d 903, 921 (E.D. Cal. 2020) (quoting *Shelton v. Ocwen Loan Servicing*, No. 18-CV-02467-AJB-WVG, 2019 WL 4747669, at \*10 (S.D. Cal. Sept. 30, 2019)). "By proscribing any unlawful business practice, the UCL borrows violations of other laws and treats them as unlawful practices that the unfair competition law makes independently actionable." *Id.* (citing *Alvarez v. Chevron Corp.*, 656 F.3d 925, 933 n.8 (9th Cir. 2011)).

The Sherman Law, California Health & Safety Code §§ 109875, et seq., explicitly adopts all federal food and nutrition labeling requirements as its own: "All food labeling regulations and any amendments to those regulations adopted pursuant to the federal act, in effect on January 1, 1993, or adopted on or after that date shall be the food labeling regulations of this state." Cal.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Health & Saf. Code § 110100. Therefore, the federal regulations governing nutrient content claims articulated in 21 C.F.R. § 101.13 are the regulations governing nutrient content claims in California. Federal regulations provide that nutrient content claims "may not be made on the label or in the labeling of foods unless the claim is made in accordance with this regulation" and other specified regulations. 21 C.F.R. § 101.13(b). The regulations define an "expressed nutrient content claim" as "any direct statement about the level (or range) of a nutrient in the food, e.g., "low sodium" or "contains 100 calories." *Id.* § 101.13(b)(1). The regulations define an "implied nutrient content claim" as any claim that: (i) Describes the food or ingredient therein in a manner that suggests the nutrient is absent or present in a certain amount (e.g., "high in oat bran"); or (ii) Suggests that a food, because of its nutrient content, may be useful in maintaining healthy dietary practices, where there is also

- implied or explicit information about the nutrient content of the food (e.g., "healthy").
- Id. § 101.13(b)(2). Further, "no nutrient content claims may be made on food intended specifically for use by infants and children less than 2 years of age," with certain exceptions. *Id.* § 101.13(b)(3).

The Court finds persuasive Plaintiff's citation to LeGrand v. Abbott Laboratories, 655 F. Supp. 3d 871, 889 (N.D. Cal. 2023), for the assertion that "packaging statements may be viewed in conjunction with nearby nutritional statements." (ECF No. 19 at 17.) As Plaintiff notes, in LeGrand, the court found the phrase "All-in-one blend to support your health" was an implied nutrient content claim where it was followed by phrases "HMB \* Protein \* Vitamin D \* Omega-3 ALA." 655 F. Supp. 3d at 899. The court also noted "the FDA guidance is not so exacting" as to require a nutrient content claim to "state or imply that a nutrient is present in a certain amount." Id. (internal quotation marks omitted) (citing Guidance for Industry A Labeling Guide for Restaurants and Other Retail Establishments Selling Away-from-home Foods (FDA Guidance for *Industry*), 2008 WL 2155726, at \*10 ("FDA may consider the term to be used in a nutritional context if it appears in association with an explicit or implicit claim or statement about a nutrient.")).

# Qase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 11 of 24

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Like *LeGrand*, the Court ultimately finds the reasonable inference from Plaintiff's allegations is that the challenged statements read together comprise a nutrient content claim. The Court disagrees with Defendant's assertion that the challenged statements here are like the many statements in *LeGrand*. There, the court found the statements did not constitute implied nutrient content claims because they were "not placed in close enough proximity to the underlying nutrient claims to be themselves considered nutrient content." (ECF No. 21 at 7 (citing *Le Grand*, 655 F. Supp. 3d at 888).)

Here, the Court finds the first, second, and fourth statements are close enough in proximity to constitute implied nutrient content claims when read in connection with the fifth statement. The fifth statement, which reads "At least 40% of the Daily Value: Iron • Calcium • Vitamins C, D & E," describes nutrients (iron, calcium, and vitamins C, D, and E) that are "present in a certain amount." 21 C.F.R. § 101.13(b)(2)(i). The fourth statement, "28 Important Nutrients for Growth and Development," suggests the Product "may be useful in maintaining healthy dietary practices" because of the nutrient content is expressed immediately below in the fifth statement. 21 C.F.R. § 101.13(b)(2)(ii). Further, "VITAMIN E" expressed in the second statement on the front of the label can be connected to the fifth statement of "At least 40% of the Daily Value" of Vitamin E to describe that the nutrient is "present in a certain amount." 21 C.F.R. § 101.13(b)(2)(i). Finally, the first statement "✓ IMMUNE SUPPORT," "✓ BRAIN DEVELOPMENT," and "✓ DIGESTIVE HEALTH," read in connection with the fourth and fifth statements, could plausibly suggest that Product generally "because of its nutrient content, may be useful in maintaining healthy dietary practices." 21 C.F.R. § 101.13(b)(2)(ii). Moreover, the Court finds unpersuasive Defendant's citation to *LeGrand* and FDA guidance that "a claim must appear in the same statement separated by a comma," "connective tissue," or "other visual element" in order for a non-nutrient claim to qualify as "in association with" a nutrient claim. (ECF No. 21 at 9). The FDA guidance does not contain this assertion. FDA Guidance for *Industry*, 2008 WL 2155726, at \*10.

Accordingly, the Court finds the first, second, and fourth statements collectively constitute an impermissible implied nutrient content claim because they are on "food intended specifically

for use by infants and children less than 2 years of age," and Defendant does not argue any of the exceptions apply to the label as a whole. 21 C.F.R. § 101.13(b)(3).

### ii. Third Statement

Defendant argues the third statement is conclusory and therefore Plaintiff's argument that the statement is an implied nutrient content claim fails. (ECF No. 18-1 at 13.) In opposition, Plaintiff asserts "5 HMO PREBIOTICS," when taken in context with the other challenged statements, constitutes an implied nutrient content claim. (ECF No. 19 at 18.) In reply, Defendant maintains this statement does not qualify under either subsection defining implied nutrient content claims. (ECF No. 21 at 8.)

Here, the Court agrees with Defendant that "5 HMO PREBIOTICS" does not fall under either subsection (i) or (ii) of 21 C.F.R. § 101.13(b)(2). First, the statement does not describe a food or ingredient "that suggests the nutrient is absent or present in a certain amount." *Id.*Second, the statement does not suggest the Product, because of its nutrient content, "may be useful in maintaining health dietary practices." *Id.* The Court further finds persuasive Defendant's argument that "to the extent Plaintiff is arguing that this statement is made in association with another claim about a nutrient, Plaintiff does not identify what nutrient claim that is." (ECF No. 21 at 8.)

Accordingly, the Court finds the third statement does not constitute an impermissible implied nutrient content claim.

## iii. Fifth Statement

Defendant argues the fifth statement, which Plaintiff alleges is both an expressed and implied nutrient content claim, is explicitly permitted by FDA regulations. (ECF No. 18-1 at 14.) Defendant notes the regulations allow for a statement "that describes the percentage of a vitamin or mineral in the food, including foods intended specifically for use by infants and children less than 2 years of age, in relation to a Reference Daily Intake (RDI)." (*Id.* (quoting 21 C.F.R. § 101.13(q)(3)).) In opposition, Plaintiff fails to respond to this argument and instead generally contends she adequately alleges this statement constitutes an expressed or implied nutrient content claim. (*See* ECF No. 19 at 19.) In reply, Defendant highlights that Plaintiff "wholly

#### Case 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 13 of 24

ignores" the argument that the fifth statement is permissible. (ECF No. 21 at 9.)

Federal regulations provide that "[e]xcept for claims regarding vitamins and minerals described in paragraph (q)(3) of this section, no nutrient content claims may be made on food intended specifically for use by infants and children less than 2 years of age[.]" 21 C.F.R. § 101.13(b)(3). Paragraph (q)(3) states:

> A statement that describes the percentage of a vitamin or mineral in the food, including foods intended specifically for use by infants and children less than 2 years of age, in relation to a Reference Daily Intake (RDI) . . . may be made on the label or in labeling of a food without a regulation authorizing such a claim for a specific vitamin or mineral unless such claim is expressly prohibited by the regulation[.]

*Id*.§ 101.13(q)(3)(i).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Here, the Court agrees with Defendant that the fifth statement falls into the exception listed in 21 C.F.R. § 101.13(q)(3)(i). The fifth statement is permitted because it describes the percentage (at least 40%) of a vitamin or mineral (iron, calcium, and vitamins C, D, and E) in relation to RDI (Daily Value). Further, Plaintiff concedes this argument in her failure to respond in opposition. See Crandall v. Teamsters Loc. No. 150, No. 2:23-CV-03043-KJM-CSK, 2024 WL 3889916, at \*5 (E.D. Cal. Aug. 20, 2024) (finding plaintiff abandoned claims not raised in opposition to defendants' motion to dismiss). Accordingly, the Court finds the fifth statement is explicitly permitted by the FDA regulations, and by extension, California law.<sup>3</sup> See Cal. Health & Saf. Code § 110100.

Accordingly, the Court finds the fifth statement is not an impermissible nutrient content claim because it falls squarely under an exemption.

In sum, because the Court finds the first, second, and fourth statements collectively constitute an impermissible implied nutrient content claim in violation of federal and California regulations, the Court finds Plaintiff adequately establishes a claim under the "unlawful" prong of the UCL. Accordingly, Defendant's motion to dismiss Plaintiff's "unlawful" UCL claim is

13

26

27

28

Because the Court finds the fifth statement is permitted under state and federal regulations, it declines to address Defendant's alternative argument regarding preemption. (See ECF No. 18-1 at 15 n.2.)

DENIED.

## B. Fraud Claim

Plaintiff alleges several claims grounded in fraud — namely, the CLRA, FAL, the "fraudulent" UCL, and common law fraud claims. (ECF No. 1 at 18–20, 23–24, 26–29.)

Defendant moves to dismiss these claims, arguing (1) Plaintiff has failed to plead them with particularity required under Rule 9(b) and (2) Plaintiff has failed to plausibly allege any of the challenged statements are misleading to reasonable consumers. (ECF No. 18-1 at 15.) The Court will consider Defendant's arguments in turn.

i. Whether Plaintiff Pleads Fraud Claims with Particularity Under Rule 9(b)

Defendant argues Plaintiff has not explained what makes the challenged statements misleading, as opposed to merely allegedly violating FDA regulations precluding certain nutrient content claims on products intended for children under two years old. (*Id.* at 16.) Defendant further argues Plaintiff does not explain with particularity how the Product is "harmful," as she alleges. (*Id.*) Defendant also contends Plaintiff's fraud theory is "indistinguishable" from that in *Davidson v. Sprout Foods*, 106 F.4th 842, 853 (9th Cir. 2024), which the Ninth Circuit rejected. (*Id.* at 16–17.)

In opposition, Plaintiff asserts Rule 9(b) only requires Plaintiff to plead knowledge generally (not to prove it prior to discovery). (ECF No. 19 at 11.) Plaintiff further asserts it is not fatal to the Complaint "that it does not describe a single specific transaction" or "a specific number or precise time frame." (*Id.* at 12.) Plaintiff notes district courts have held that time, place, and content of a fraud by omission can succeed without the same level of specificity required by normal fraud because requiring a plaintiff to identify the precise time, place, and content of an event that did not occur would effectively gut state laws prohibiting fraud by omission. (*Id.*) Plaintiff maintains the Complaint sufficiently pleads particularity of circumstances relating to the Product, violations of FDA law of its labels, the misleading statements, and reliance. (*Id.*) Plaintiff also contends Defendant's analogy to *Davidson* is incorrect because *Davidson* focused on how the fraud theory's core component involved a

showing that the messages were false *and* harmful. (*Id.* at 15.)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

In reply, Defendant highlights that Plaintiff does not provide an answer to its argument regarding *Davidson*, 106 F.4th 842, other than a "half-hearted" attempt to distinguish the case. (ECF No. 21 at 10.) Defendant maintains that what was missing in *Davidson* were facts plausibly pleading why the message was false or harmful, which is the same as what Plaintiff's Complaint is missing in the instant case. (*Id.* at 11.)

"[W]hile a federal court will examine state law to determine whether the elements of fraud have been [pleaded] sufficiently to state a cause of action, the Rule 9(b) requirement that the circumstances of the fraud must be stated with particularity is a federally imposed rule." Vess v. Ciba-Geigy Corp. USA, 317 F.3d 1097, 1103 (9th Cir. 2003) (emphasis in original). Even "where fraud is not a necessary element of a claim," a plaintiff may allege and rely entirely on "a unified course of fraudulent conduct" as the basis of a claim. Id. In such cases, those claims are "grounded in fraud" and must be pleaded to satisfy the particularity requirement of Rule 9(b). *Id*. Courts have held CLRA, FAL, and UCL claims are grounded in fraud and Rule 9(b) is applicable to false representation allegations in this context. Weiss v. Trader Joe's Co., No. 8:18-cv-01130-JLS-GJS, 2018 WL 6340758, at \*7 (C.D. Cal. Nov. 20, 2018) (citing *Kearns v. Ford Motor Co.*, 567 F.3d 1120, 1125 (9th Cir. 2009); Brazil v. Dole Food Co., 935 F. Supp. 2d 947, 963–64 (N.D. Cal. 2013)), aff'd sub nom., 838 F. App'x 302 (9th Cir. 2021). To comply with Rule 9(b), a plaintiff "must allege the who, what, when, where, and how of the misconduct charged." *Id.* (internal quotations and citation omitted). A plaintiff must also "allege with specificity what products they purchased, on what statements they relied in making those purchases, and why those statements were false or misleading." Haley v. Macy's, Inc., 263 F. Supp. 3d 819, 824 (N.D. Cal. 2017).

Here, the Court finds Plaintiff's CLRA, FAL, UCL, and common law fraud claims are "grounded in fraud" and therefore Plaintiff's Complaint needs to satisfy Rule 9(b)'s heightened pleading standards. Defendant does not seem to dispute the who, what, when, or where of the alleged misconduct, but rather simply the "how" of the alleged misconduct — namely, "how" the Product labeling is allegedly misleading and how the Product is allegedly "harmful." (ECF No.

18-1 at 16.)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Plaintiff alleges: "[T]he nutrient content claims on the Product misleads purchasers into believing that the products provide physical health benefits for children under two years of age in order to induce parents into purchasing Defendants' products. In fact, the Product is harmful both nutritionally and developmentally for children under two." (ECF No. 1 at 2.) Throughout the Complaint, Plaintiff largely repeats the same allegations. (See id.) Somewhat more specifically, Plaintiff alleges the nutrient content claims on the Product's front labels "mislead[s] consumers into believing that foods for children under two should be purchased based on the quantities of the listed nutrients, when other considerations are just as, or more, important." (*Id.* at 12.) Plaintiff further alleges "[t]he Guidelines also recommend that children 'younger than age 2' completely '[a]void foods and beverages with added sugars" and the Product "has 4 grams of added sugars." (Id.) According to Plaintiff, "[d]ietary needs for children under two are also different from those of adults because the optimal diet for children under two also has to address needs beyond mere nutrition, such as developing neural pathways in the brain to establish healthy eating habits and developing gross and fine motor skills." (Id.) Plaintiff finally alleges that "[a]s a result of Defendant['s] unlawful and misleading nutrient content claims, the Product has no, or at a minimum, much lower value to Plaintiff." (Id. at 15.) The Court finds these allegations are sufficient to meet Rule 9(b)'s heightened pleading standards. Plaintiff's allegations explain how or why the alleged nutrient content claims are misleading or harmful. Haley, 263 F. Supp. 3d at 824.

The Court further finds Defendant's citation to *Davidson* to be unpersuasive. In *Davidson*, plaintiffs alleged Sprout's baby food pouches were harmful because (1) "the products 'contain high amounts of free sugars' accompanied by a list of the grams of sugar in some of the products" and (2) "pouch-based foods in general may be unhealthy for children, nutritionally and developmentally." 106 F.4th at 853. The Ninth Circuit agreed the district court correctly identified the deficiencies in these allegations. *Id.* The court noted the allegations about sugar lack context because plaintiffs did not "explain at what level sugars become harmful or why the levels of sugar in these products, in particular, could cause harm." *Id.* The court noted the

#### 

allegations about "pouch-based foods" and allegations of harm relied "on hypotheticals and contingencies outside the scope of this case." *Id.* The court finally noted that "plaintiffs never actually alleged that Sprout's products cause any of these harms." *Id.* Unlike plaintiffs in *Davidson*, here, Plaintiff explicitly alleges the Dietary Guidelines recommend that children younger than age two should completely avoid foods and beverages with *any* added sugar. (ECF No. 1 at 12.) Plaintiff further explains in the Complaint that "the period of 0-24 months 'is key for establishing healthy dietary patterns that may influence the trajectory of eating behaviors and health throughout the life course . . . Children in this age group consume small quantities of food, so it's important to make every bite count!" (*Id.*)

The Court therefore finds that Plaintiff pleads her fraud claims with the level of particularity required by Rule 9(b). Accordingly, Defendant's motion to dismiss Plaintiff's fraudbased claims — the CLRA, FAL, the "fraudulent" UCL, and common law fraud claims — is DENIED.

ii. Whether Plaintiff Plausibly Alleges the Challenged Statements areMisleading to Reasonable Consumers

Defendant argues Plaintiff does not allege that any challenged statement is false in even conclusory terms or allege facts amounting to falsity, but instead alleges they are "misleading." (ECF No. 18-1 at 18.) Defendant contends Plaintiff does not plausibly plead they are misleading either, addressing each statement in turn.<sup>4</sup> (*Id.*) Defendant asserts that Plaintiff does not allege: (1) the Product does not contribute to immune support, brain development, or digestive health; (2) the Product does not contain DHA, lutein, or vitamin E; (3) the Product does not contain 5 HMO prebiotics; (4) two servings of the Product do not have 28 nutrients, or that those nutrients are not important for growth and development, no matter how much sugar the Product contains; and (5) the Product does not contain at least 40% of the Daily Values for iron, calcium, or vitamins C, D,

Defendant also argues that, to the extent Plaintiff alleges the statements are misleading because they are nutrient content claims, none of the challenged statements are misleading because they are not nutrient content claims. (*Id.* at 18–19.) The Court declines to address this argument because, as stated above, it finds Plaintiff adequately alleges the first, second, and fourth statements, when read in conjunction with the fifth statement, comprise a nutrient content claim.

or E. (*Id.* at 18–19.)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

In opposition, Plaintiff argues she adequately pleads Rule 9(b) particularity of misleading labels under the reasonable consumer test, which means she "needs only to minimally allege, with particularity, such statements have the capacity, likelihood, or tendency to deceive or confuse the public, and need not allege nor prove falsity." (ECF No. 19 at 12–13.) Plaintiff also maintains she does not have to plead allegations of "harmfulness" to state claims under the UCL, FAL, and CLRA, and it is sufficient to allege the labels are misleading without harm to survive the pleadings stage. (*Id.* at 14.)

In reply, Defendant maintains Plaintiff fails to plausibly allege how the statements are misleading to consumers "acting reasonably in the circumstances" and Plaintiff fails to point to well-pleaded allegations to show how or why each statement is misleading. (ECF No. 21 at 11 (quoting *McGinity v. Procter & Gamble Co.*, 69 F.4th 1093, 1097 (9th Cir. 2023)).)

The standard for claims under the UCL, FAL, and CLRA is the "reasonable consumer" test, which requires a plaintiff to show that members of the public are likely to be deceived by the business practice or advertising at issue, or that "the product labeling and ads promoting the products have a meaningful capacity to deceive consumers." See McGinity, 69 F.4th at 1097; Williams v. Gerber Prod. Co., 552 F.3d 934, 938 (9th Cir. 2008); see also Consumer Advocates v. Echostar Satellite Corp., 113 Cal. App. 4th 1351, 1360 (2003). "The California Supreme Court has recognized that [the UCL, FAL, and CLRA] prohibit explicitly false advertising and advertising that is "either actually misleading[,] or which has the capacity, likelihood[,] or tendency to deceive or confuse the public." McGinity, 69 F.4th at 1097 (quoting Kasky v. Nike, Inc., 27 Cal. 4th 939, 951 (2002)). This "reasonable consumer" test "requires more than a mere possibility that the label might conceivably be misunderstood by some few consumers viewing it in an unreasonable manner." Id. (internal quotation marks and citations omitted). Rather, it "requires a probability that a significant portion of the general consuming public or of targeted consumers, acting reasonably under the circumstances, could be misled." *Id.* (internal quotation marks and citations omitted). Courts often analyze the UCL, FAL, and CLRA statutes together. See, e.g., Consumer Advocates, 113 Cal. App. 4th at 1360–62 (analyzing representations under

	ase 2.24 cv 02427 TEN SCIX Document 25 Thea 00/11/25 Tage 13 01 24				
1	the CLRA, UCL, and FAL together); Tait v. BSH Home Appliances, Corp., No. SACV 10-00711				
2	DOC (ANx), 2011 WL 3941387, at *2 (C.D. Cal. Aug. 31, 2011) (same). The Ninth Circuit has				
3	also noted that whether a practice is deceptive "is an issue of fact not generally appropriate for				
4	decision on a motion to dismiss" and that it is a "rare situation in which granting a motion to				
5	dismiss is appropriate[.]" LeGrand, 655 F. Supp. 3d at 890 (citing Williams, 552 F.3d at 938–				
6	39).				
7	Here, Plaintiff points to the following allegations <sup>5</sup> in support of her contention that the				
8	Product's label is misleading or that the statements "have the capacity, likelihood, and tendency				
9	to deceive or confuse the public":				
10	<ul> <li>"Defendants misbrand the Product by making nutrient</li> </ul>				
11	content claims that are strictly prohibited by the FDA, and by misleading purchasers into believing that its Product provides				
12	physical health benefits[.]" (ECF No. 1 ¶ 36.)				

• "Foods intended for children less than two are prohibited from making such nutrient content claims . . . the Product is accordingly misbranded." (*Id.* ¶¶ 37–38.)

- "The nutrient content claims on the Product misleads reasonable consumers into believing the Product will provide physical health benefits for their children, when in fact the Product is harmful." (*Id.* ¶ 41.)
- "By echoing the nutritional concerns of parents and including vague buzzwords, claims, and graphics regarding growth, development, immune support, brain development, and digestive health, Defendant[] induce[s] and mislead[s] consumers into purchasing their Product for fear that a diet without the Product is nutritionally inadequate for their toddlers." (*Id.* ¶ 41.)
- "For these reasons, Defendant[] marketing the Product as providing physical health benefits for toddlers being a healthful and safe source of nutrients for babies and toddlers is misleading to reasonable consumers[.]" (*Id.* ¶ 52.)

First, Plaintiff adequately alleges the Product "misleads reasonable consumers" into believing it will "provide physical health benefits for children" by explaining that the Dietary

This list is not a comprehensive list of what Plaintiff asserts are her relevant allegations, but a smaller selection that slightly less repetitive and focuses on the crux of Plaintiff's allegations. (*See* ECF No. 19 at 13–14.)

#### 

Guidelines "recommend that children 'younger than age 2' completely '[a]void foods and beverages with added sugars." (*Id.* at 12.) As the Court previously noted, Plaintiff sufficiently asserts why dietary needs for children under two years of age are different from the needs of adults and why nutrition in the first 24 months of life is important. (*Id.*) Second, the Court finds unpersuasive Defendant's assertion that the "statements never mention sugar" and "[a]ny reasonable consumer interested in Go & Grow's sugar content could review the product's ingredient list to dispel or ameliorate any confusion that might be raised by other truthful labeling statements." (ECF No. 18-1 at 18 (internal quotation marks and citation omitted).) Taking as true Plaintiff's allegations that any added sugars before two years of age goes against the Dietary Guidelines and drawing all inferences in Plaintiff's favor, the Court finds it sufficient for Plaintiff to allege that Defendant uses the first, second, and fourth statements on its Product, which Plaintiff sufficiently alleges is an unlawful implied nutrient content claim, which leads reasonable consumers to believe the product indeed provides those physical health benefits when in fact the Product is harmful — i.e., the Product does not actually provide the physical health benefits it claims to provide.

Based on the foregoing, the Court finds Plaintiff adequately establishes why the statements on the Product's label are "either actually misleading[,] or [have] the capacity, likelihood[,] or tendency to deceive or confuse the public." *McGinity*, 69 F.4th at 1097.

Accordingly, Defendant's motion to dismiss Plaintiff's fraud-based claims based on the "reasonable consumer" test is DENIED.

### C. UCL "Unfair" Claim

Defendant argues that, to the extent Plaintiff relies on the "unfair" prong of the UCL, this claim also fails because it entirely overlaps with other claims subject to dismissal. (ECF No. 18-1 at 19.) Defendant further argues Plaintiff fails to state a claim under the "unfair" prong because the Complaint fails to allege facts to satisfy: (1) the "tethering" test because it does not reference any public policy and none of the challenged statements qualify as an impermissible nutrient content claim; or (2) the "balancing" test because Plaintiff fails to allege her injury was "substantial," her injury was not "outweighed by countervailing benefits," or that consumers

# Qase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 21 of 24

could have avoided the injury by reviewing the Nutrition Facts panel. (*Id.* at 20–21.)

In opposition, Plaintiff maintains the UCL permits violations of other laws to be treated as unfair competition that is independently actionable, and she adequately alleges Defendant violates the UCL by fraudulent and unlawful practices. (ECF No. 19 at 20–21.) Plaintiff therefore maintains Defendant's arguments regarding the Complaint's failure to satisfy the tethering or balancing test are "beside the point." (*Id.* at 21.)

Indeed, the California Supreme Court has held "[t]he UCL's scope is broad" and "[b]y defining unfair competition to include any 'unlawful . . . business or practice," the law "permits violations of other laws to be treated as unfair competition that is independently actionable." *Kasky*, 27 Cal. 4th at 949 (emphasis in original).

Here, as set forth above, the Court finds Plaintiff adequately establishes a claim under the "unlawful" prong of the UCL. The Court therefore similarly finds Plaintiff adequately establishes a claim under the "unfair" prong of the UCL. Accordingly, Defendant's motion to dismiss Plaintiff's "unfair" UCL claim is DENIED.

# D. <u>Unjust Enrichment Claim</u>

Defendant argues in a footnote that Plaintiff's unjust enrichment claim suffers from the same defects as her statutory and common law fraud claims and should therefore be dismissed on those bases. (ECF No. 18-1 at 21 n.3.) Defendant further argues this claim also fails because it is not a standalone cause of action in California. (*Id.*) In opposition, Plaintiff maintains that if any of Plaintiff's other claims survive, her claim for unjust enrichment must survive. (ECF No. 19 at 24.) In reply, Defendant notes Plaintiff concedes this claim "rises and falls with her other claims." (ECF No. 21 at 14 n.3.)

California courts have held "[u]njust enrichment is not a cause of action," but rather it is "just a restitution claim." *De Havilland v. FX Networks, LLC*, 21 Cal. App. 5th 845, 870 (2018). If there is "no actionable wrong, there is no basis for the relief." *Id.*; *see also Astiana v. Hain Celestial Grp.*, 783 F.3d 753, 762 (9th Cir. 2015) ("[I]n California, there is not a standalone cause of action for 'unjust enrichment,' which is synonymous with 'restitution.'"). Further, "[w]hen a plaintiff alleges unjust enrichment, a court may construe the action as a quasi-contract claim

seeking restitution." Astiana, 783 F.3d at 762.

Here, because Plaintiff's adequately alleges sufficient facts to state "unlawful" and "unfair" UCL claims, those claims still stand. The Court therefore declines to dismiss Plaintiff's unjust enrichment claim. Accordingly, Defendant's motion to dismiss Plaintiff's unjust enrichment claim is DENIED.

## E. <u>Injunctive Relief Claim</u>

Defendant argues Plaintiff's request for injunctive relief fails because (1) she lacks standing to pursue injunctive relief because she does not allege any "real or immediate threat that [she] will be wronged again" in a similar way. (ECF No. 18-1 at 21–22.) In opposition, Plaintiff maintains numerous district judges have found standing where "a consumer would not be able to reasonably rely on a defendant's label in the future and expressed an intent to purchase a future product if properly labeled . . . or the veracity of the claims on the labels could be easily or readily verified by looking to other information on the label." (ECF No. 19 at 21–22 (internal citations removed).)

A plaintiff must establish constitutional standing for each type of relief she requests. Davidson v. Kimberly-Clark Corp., 889 F.3d 956, 967 (9th Cir. 2018). While past wrongs alone are insufficient to establish standing, they can be "evidence bearing on whether there is a real and immediate threat of repeated injury." *Id.* (quoting City of Los Angeles v. Lyons, 461 U.S. 95, 102 (1983)). The Ninth Circuit has held that a previously deceived customer may have standing to seek an injunction against false labeling, despite knowing or suspecting the advertising was false at the time of original purchase, because the consumer may suffer an "actual and imminent, not conjectural or hypothetical" threat of future harm. *Id.* at 969 (quoting Summers v. Earth Island Inst., 555 U.S. 488, 493 (2009)). The Ninth Circuit has articulated two possible types of harm warranting an injunction in such cases, where the consumer plausibly alleges: (1) "she will be unable to rely on the product's advertising or labeling in the future, and so will not purchase the

Defendant also argues Plaintiff's request for injunctive relief fails because she does not allege she lacks an adequate remedy at law. (ECF No. 18-1 at 22.) However, because the Court finds Plaintiff fails to adequately establish standing for injunctive relief, it declines to address Defendant's additional argument.

#### 

product although she would like to"; or (2) "she might purchase the product in the future, despite the fact it was once marred by false advertising or labeling, as she may reasonably, but incorrectly, assume the product was improved." *Id.* at 969–70.

Here, Plaintiff alleges in the Complaint that she purchased the Product for her child when he was one year old. (ECF No. 1 at 15.) Plaintiff alleges she purchased the Product in July 2021 for about five to six months thereafter. (*Id.*) Plaintiff does not allege she purchased the Product after this five to six month period. (*See id.*) Plaintiff further does not plausibly allege that she would like to purchase the Product again in the future and she will be unable to rely on its advertising or labeling. (*Id.*) Nor does she allege she might purchase the Product in the future on a reasonable but incorrect assumption that the Product was improved. (*Id.*) The Court therefore agrees with Defendant that Plaintiff fails to establish any "actual and imminent" threat that she will be wronged again by the Product. The Court finds the instant case is unlike Plaintiff's citation to *Krommenhock v. Post Foods, LLC*, 255 F. Supp. 3d 938, 967 (N.D. Cal. June 1, 2017) because plaintiffs plausibly allege in *Krommenhock* that "they would be willing to purchase Post's cereals in the future if they were accurately described and the cereals were either (i) reformulated to reduce added sugar, or (ii) priced lower so they could be purchased as a treat." (ECF No. 19 at 22.) Unlike the plaintiffs in *Krommenhock*, Plaintiff fails to allege here that she would purchase the Product again in the future.

Because the Court cannot determine at this juncture "that the pleading could not possibly be cured by the allegation of other facts," the Court will grant Plaintiff leave to amend her claim for injunctive relief. *See Lopez*, 203 F.3d at 1130. Accordingly, Defendant's motion to dismiss Plaintiff's injunctive relief claim is GRANTED with leave to amend.

### IV. CONCLUSION

For the foregoing reasons, the Court GRANTS in part and DENIES in part Defendant's Motion to Dismiss (ECF No. 18) as follows:

- 1. Defendant's motion to dismiss Plaintiff's "unlawful" UCL claim is DENIED;
- Defendant's motion to dismiss Plaintiff's fraud-based claims the CLRA, FAL, the "fraudulent" UCL, and common law fraud claims — is DENIED;

(	ase 2:24-cv-02427-TLN-SCR Document 29 Filed 08/11/25 Page 24 of 24
1	3. Defendant's motion to dismiss Plaintiff's "unfair" UCL claim is DENIED;
2	4. Defendant's motion to dismiss Plaintiff's unjust enrichment claim is DENIED; and
3	5. Defendant's motion to dismiss Plaintiff's injunctive relief claim is GRANTED
4	with leave to amend.
5	Plaintiff may file an amended complaint not later than thirty (30) days from the electronic
6	filing date of this Order. Defendant shall file a responsive pleading not later than twenty-one (21)
7	days from the electronic filing date of the amended complaint. If Plaintiff opts not to file an
8	amended complaint, the case shall proceed on Plaintiff's remaining claims in the action.
9	IT IS SO ORDERED.
10	Date: August 8, 2025
11	$\mathcal{A} = \mathcal{A} = $
12	and the
13	TROY L. NUNLEY CHIEF UNITED STATES DISTRICT JUDGE
14	CHIEF CHIED STRIES DISTRICT VODGE
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	